Advanced non-small-cell lung cancer: Benefit of chemotherapy in symptom control

被引：0

作者：

Margery, J

Le Moulec, S

Grassin, F

Bauduceau, O

Dot, JM

Vedrine, L

Natali, F

Guigay, JL

机构：

[1] Hop Instruct Armees Percy, Serv Malad Resp, F-92140 Clamart, France

[2] Hop Instruct Armees Val Grace, Serv Oncol, F-75015 Paris, France

[3] Hop Instruct Armees Clermont Tonnerre, Serv Pneumol, F-29240 Brest, France

来源：

BULLETIN DU CANCER | 2003年 / 90卷 / 10期

关键词：

non-small-cell lung cancer; chemotherapy; symptom control; cancer patient's expectation;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chemotherapy in advanced non-small-cell lung cancer may be a controversy because it is only palliative and costly. Benefit of chemotherapy is nevertheless clear in survival and particularly life quality. Beside this technical criteria, two other factors have an impact on the therapeutic decision: symptom control and patient's persona expectations. The aim of the strategy is to determine an acceptable compromise in each situation.

引用

收藏

页码：917 / 918

页数：2

相关论文

共 11 条

[1] Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome [J].

Anderson, H. ;

Hopwood, P. ;

Stephens, R. J. ;

Thatcher, N. ;

Cottier, B. ;

Nicholson, M. ;

Milroy, R. ;

Maughan, T. S. ;

Falk, S. J. ;

Bond, M. G. ;

Burt, P. A. ;

Connolly, C. K. ;

McIllmurray, M. B. ;

Carmichael, J. .

BRITISH JOURNAL OF CANCER, 2000, 83 (04) :447-453

[2] Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer [J].

Berthelot, JM ;

Will, BP ;

Evans, WK ;

Coyle, D ;

Earle, CC ;

Bordeleau, L .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1321-1329

[3] Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life [J].

Cullen, MH ;

Billingham, LJ ;

Woodroffe, CM ;

Chetiyawardana, AD ;

Gower, NH ;

Joshi, R ;

Ferry, DR ;

Rudd, RM ;

Spiro, SG ;

Cook, JE ;

Trask, C ;

Bessell, E ;

Connolly, CK ;

Tobias, J ;

Souhami, RL .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3188-3194

[4]

Demange C, 2003, B CANCER, V90, P284

[5] Chemotherapy use among medicare beneficiaries at the end of life [J].

Emanuel, EJ ;

Young-Xu, Y ;

Levinsky, NG ;

Gazelle, G ;

Saynina, O ;

Ash, AS .

ANNALS OF INTERNAL MEDICINE, 2003, 138 (08) :639-643

[6]

Le Guen Y, 2003, B CANCER, V90, P199

[7] A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer [J].

Massarelli, E ;

Andre, F ;

Liu, DD ;

Lee, JJ ;

Wolf, M ;

Fandi, A ;

Ochs, J ;

Le Chevalier, T ;

Fossella, F ;

Herbst, RS .

LUNG CANCER, 2003, 39 (01) :55-61

[8] ATTITUDES TO CHEMOTHERAPY - COMPARING VIEWS OF PATIENTS WITH CANCER WITH THOSE OF DOCTORS, NURSES, AND GENERAL PUBLIC [J].

SLEVIN, ML ;

STUBBS, L ;

PLANT, HJ ;

WILSON, P ;

GREGORY, WM ;

ARMES, PJ ;

DOWNER, SM .

BRITISH MEDICAL JOURNAL, 1990, 300 (6737) :1458-1460

[9] Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: Changes in performance status and tumour-related symptoms [J].

Thatcher, N ;

Anderson, H ;

Betticher, DC ;

Ranson, M .

ANTI-CANCER DRUGS, 1995, 6 :39-48

[10] Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer:: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine [J].

Vansteenkiste, J ;

Vandebroek, J ;

Nackaerts, K ;

Dooms, C ;

Galdermans, D ;

Bosquée, L ;

Delobbe, A ;

Deschepper, K ;

Van Kerckhoven, W ;

Vandeurzen, K ;

Deman, R ;

D'Odemont, JP ;

Siemons, L ;

Van den Brande, P ;

Dams, N .

LUNG CANCER, 2003, 40 (02) :191-199